Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) will be releasing its earnings data on Wednesday, August 2nd. Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) last released its quarterly earnings data on Monday, May 8th. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01. The business had revenue […]
Akebia Therapeutics, Inc. (NASDAQ:AKBA – Get Free Report) saw a large growth in short interest in June. As of June 30th, there was short interest totalling 4,840,000 shares, a growth of 11.3% from the June 15th total of 4,350,000 shares. Based on an average daily volume of 1,800,000 shares, the short-interest ratio is currently 2.7 […]
Piper Sandler upgraded shares of Akebia Therapeutics (NASDAQ:AKBA – Get Rating) from a neutral rating to an overweight rating in a research note released on Wednesday, The Fly reports. A number of other brokerages have also issued reports on AKBA. StockNews.com lowered Akebia Therapeutics from a buy rating to a hold rating in a research […]
Akebia Therapeutics, Inc. (NASDAQ:AKBA – Get Rating) was the recipient of a significant decline in short interest during the month of May. As of May 15th, there was short interest totalling 4,070,000 shares, a decline of 9.6% from the April 30th total of 4,500,000 shares. Based on an average daily volume of 1,720,000 shares, the […]
Akebia Therapeutics, Inc. (NASDAQ:AKBA – Get Rating) was the target of a significant drop in short interest in the month of May. As of May 15th, there was short interest totalling 4,070,000 shares, a drop of 9.6% from the April 30th total of 4,500,000 shares. Based on an average daily trading volume, of 1,720,000 shares, […]